- Antisense Therapeutics (ANP) announces its new proteomics data will be presented in a virtual congress
- The data on Antisense’s ATL1102 is set to be presented at the 26th World Muscle Society Virtual Annual Congress 2021, being held over four days from September 20
- ATL1102 is an antisense inhibitor which has proven to significantly reduce the number of brain lesions in patients with relapsing-remitting multiple sclerosis
- Antisense Therapeutics is up 10 per cent, trading at 19.3 cents at 11:16 am AEST
Antisense Therapeutics (ANP) has announced its new proteomics data will be presented in a virtual congress.
The data is scheduled to be presented in a poster at the 26th World Muscle Society (WMS) Virtual Annual Congress 2021, being held over four days from September 20.
World Muscle Society is an international scientific society spanning multiple disciplines, dedicated to the neuromuscular field. This year, the congress is being held in a virtual format, consisting of scientific sessions, e-poster presentations, virtual exhibition and virtual networking.
Antisense’s poster is entitled “ATL1102 treatment in non-ambulant boys with DMD modulates latent TGF-beta-binding protein 4, and thrombospondin-1, two disease genetic modifier of ambulant DMD, and CXCL16”.
ATL1102 is an antisense inhibitor of the CD49d receptor, developed for Antisense Therapeutics for Duchenne muscular dystrophy (DMD) patients. DMD occurs as a result of mutations in the dystrophin gene which causes a substantial reduction in or absence of the dystrophin protein.
ATL1102 has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis.
Antisense Therapeutics is up 10 per cent, trading at 19.3 cents at 11:16 am AEST.